MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 885 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
KRAS G12C inhibitor 25
CAS:<p>KRAS G12C inhibitor 25 blocks SOS1-mediated GDP/GTP swap in KRAS-G12C mutants; IC50: 0.48 nM (WO2021216770A1, comp. 3).</p>Formula:C32H41N7O2Color and Shape:SolidMolecular weight:555.71B-Raf IN 5
CAS:<p>B-Raf IN 5 is a potent inhibitor of the protein kinase B-Raf (IC50: 2.0 nM). B-Raf IN 5 resists rapid metabolism and does not bind to the secondary target PXR.</p>Formula:C23H18ClF3N6O3S2Color and Shape:SolidMolecular weight:583.01KRAS inhibitor-12
CAS:<p>KRAS inhibitor-12 blocks KRAS G12C (IC50: 0.537 μM) and p-ERK in cancer cells; promising for pancreatic, colorectal, lung cancer study.</p>Formula:C19H16Cl2FN5OSColor and Shape:SolidMolecular weight:452.33HPK1-IN-33
CAS:<p>HPK1-IN-33 inhibits HPK1 with 1.7 nM potency, reduces IL-2 in Jurkat cells with 286 nM EC50, and is less effective in HPK1 KO cells.</p>Formula:C18H16ClFN6Color and Shape:SolidMolecular weight:370.81KRAS G12C inhibitor 53
CAS:<p>KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.</p>Formula:C21H14ClF2N5O2Color and Shape:SolidMolecular weight:441.82HPK1-IN-11
CAS:<p>HPK1-IN-11 is a potent HPK1 inhibitor. HPK1-IN-11 has potential for the study of HPK1-related diseases.</p>Formula:C27H25N5O2Color and Shape:SolidMolecular weight:451.52pan-KRAS-IN-3
CAS:<p>Pan-KRAS-IN-3 (Example 84) is a pan-KRAS inhibitor suitable for cancer research [1].</p>Formula:C33H32F3N5O2Purity:98%Color and Shape:SolidMolecular weight:587.63SB 203580 sulfone
CAS:<p>SB 203580 sulfone, an analog of the p38 MAP kinase inhibitor SB 203580, inhibits IL-1 production in monocytes and binds competitively with CSAID binding proteins (CSBP), inhibiting stress response signaling. It exhibits an IC50 of 0.2 μM for IL-1 inhibition and 0.03 μM for CSBP-mediated signaling inhibition [1].</p>Formula:C21H16FN3O2SColor and Shape:SolidMolecular weight:393.43AZ-TAK1
CAS:<p>"AZ-Tak1 inhibits TAK1 kinase (IC50=0.009mM), reduces p38/ERK levels, and induces apoptosis in Mino, SP53, Jeko cells with increasing efficacy at 0.1-0.5mM."</p>Formula:C25H28FN7O2Color and Shape:SolidMolecular weight:477.53AMG-548 dihydrochloride (864249-60-5 free base)
<p>AMG-548 dihydrochloride: oral p38α inhibitor, Ki: 0.5 nM; less so for p38β, Ki: 36 nM; >> p38γ/δ; blocks LPS-induced TNFα, IC50: 3 nM.</p>Formula:C29H29Cl2N5OPurity:98%Color and Shape:SolidMolecular weight:534.48HPK1-IN-35
CAS:<p>HPK1-IN-35 is a potent, selective inhibitor of HPK1, demonstrating an IC50 value of 3.5 nM.</p>Formula:C30H32N8O3SColor and Shape:SolidMolecular weight:584.69Rac1-IN-3
CAS:<p>Rac1-IN-3 (Compound 2) is a Rac1 inhibitor exhibiting an inhibitory concentration 50 (IC50) of 46.1 μM [1].</p>Formula:C21H23N7O2Purity:98%Color and Shape:SolidMolecular weight:405.45BI-0474
CAS:<p>BI-0474: KRASG12C inhibitor, IC50=7.0 nM, blocks GDP-KRAS/SOS1, anti-tumor in NCI-H358 cells & lung cancer model, for cancer research.</p>Formula:C30H37N9O2SPurity:99.61%Color and Shape:SolidMolecular weight:587.74FGTI-2734 mesylate (1247018-19-4 free base)
CAS:<p>FGTI-2734 mesylate hinders KRAS, overcoming resistance and targeting pancreatic tumors; inhibits FT and GGT with IC50s of 250 nM, 520 nM.</p>Formula:C27H35FN6O5S2Purity:98%Color and Shape:SolidMolecular weight:606.73(R)-VX-11e
CAS:<p>(R)-VX-11e is an isomer of VX-11e, a potent and selective ERK2 inhibitor with potential to inhibit tumor growth.</p>Formula:C24H20Cl2FN5O2Purity:98.73%Color and Shape:SolidMolecular weight:500.35KRAS G12C inhibitor 59
CAS:<p>KRAS G12C Inhibitor 59 is a compound with anticancer properties.</p>Formula:C32H39F6N7O5Purity:98%Color and Shape:SolidMolecular weight:715.69B-Raf IN 15
CAS:<p>B-Raf IN 15 is a BRAF inhibitor that inhibits BRAFWT and BRAFV600E and can be used to study melanoma and cancer.</p>Formula:C19H15N3OSPurity:98%Color and Shape:SolidMolecular weight:333.41KRAS G12C inhibitor 61
CAS:<p>KRAS G12C inhibitor 61 (Example 3) demonstrates potent activity by inhibiting phospho-ERK 1/2 in MIA PaCa-2 cells, reflected in an IC50 value of 9 nM.</p>Formula:C31H33ClFN7O2Purity:98%Color and Shape:SolidMolecular weight:590.09MNK inhibitor 9
CAS:<p>MNK inhibitor 9 potently blocks MNK1/2 (IC50: 0.003 µM each), is cell-permeable, and useful for tumor research.</p>Formula:C25H29N9OColor and Shape:SolidMolecular weight:471.56DL-threo dihydrosphingosine
CAS:<p>DL-threo dihydrosphingosine blocks ERK, inhibits smooth muscle proliferation, and works against growth factor/G-protein ERK activation.</p>Formula:C18H39NO2Color and Shape:SolidMolecular weight:301.51KRAS inhibitor-11
<p>KRAS inhibitor-11 is a KRAS inhibitor .</p>Formula:C29H47N9O6Color and Shape:SolidMolecular weight:617.74KRAS G12C inhibitor 1R
CAS:<p>KRAS G12C inhibitor 1R can be used in studies about Ras.</p>Formula:C31H36ClFN6O2Color and Shape:SoildMolecular weight:579.11GGTI-297
CAS:<p>GGTI-297 is a potent, cell-permeable, and selective peptidomimetic inhibitor of GGTase I compared to Farnesyl Transferase (FTase).</p>Formula:C26H31N3O3SColor and Shape:SolidMolecular weight:465.61Raf inhibitor 3
CAS:<p>Raf inhibitor 3 (Example 30), a potent inhibitor of both B-Raf and C-Raf, exhibits IC50 values below 15 nM. It is applicable in cancer research studies [1].</p>Formula:C18H19FN8O2SPurity:98%Color and Shape:SolidMolecular weight:430.46KRAS inhibitor-14
CAS:<p>KRAS inhibitor-14 targets G12C (IC50: 0.249 μM) and inhibits p-ERK in cancer cells; promising for pancreatic, colorectal, lung cancers.</p>Formula:C20H15Cl3FN3O2SColor and Shape:SolidMolecular weight:486.77Inflachromene
CAS:<p>Inflachromene (ICM) is an inhibitor of HMGB1 and HMGB expression with anti-inflammatory activity.Inflachromene is used in the study of epilepsy.</p>Formula:C21H19N3O4Purity:97.36% - 99.88%Color and Shape:SolidMolecular weight:377.39Laxiflorin B
CAS:<p>Laxiflorin B, a novel selective inhibitor of ERK 1/2 derived from herbal sources, exhibits antitumor activity [1].</p>Formula:C20H24O5Purity:98%Color and Shape:SolidMolecular weight:344.4HPK1-IN-13
CAS:<p>HPK1-IN-13 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.</p>Formula:C25H24FN5O2Color and Shape:SolidMolecular weight:445.49Glecirasib
CAS:<p>Glecirasib (JAB-21822,KRAS G12C inhibitor 36) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits KRAS G12C-dependent signaling</p>Formula:C31H26ClF4N7O2Purity:99.7% - >99.99%Color and Shape:SolidMolecular weight:640.03GSK1790627
CAS:<p>GSK1790627, the N-deacetylated metabolite of Trametinib, represents an orally active MEK inhibitor that promotes autophagy and triggers apoptosis [1].</p>Formula:C24H21FIN5O3Color and Shape:SolidMolecular weight:573.36SOS1-IN-5
CAS:<p>SOS1-IN-5, a potent pyrimidine inhibitor, disrupts RAS-SOS1, blocking KRAS activation.</p>Formula:C26H31F3N4O5Color and Shape:SolidMolecular weight:536.54ZG1077
CAS:<p>ZG1077, a covalent KRAS G12C inhibitor, is utilized in non-small cell lung cancer (NSCLC) research.</p>Formula:C33H33F2N5O5SColor and Shape:SolidMolecular weight:649.71KRAS G12C mutant protein inhibitor A-1
CAS:<p>KRAS G12C mutant protein inhibitor A-1 can be used in studies about Ras.</p>Formula:C31H26ClF4N7O2Color and Shape:SolidMolecular weight:640.03ERK1/2 inhibitor 9
CAS:<p>ERK1/2 Inhibitor 9 (Probe 1), a covalent antagonist of ERK1/2, exhibits sub-micromolar efficacy in cellular assays (A375 GI50=0.47 μM) and facilitates the</p>Formula:C31H32ClN7O3Purity:98%Color and Shape:SolidMolecular weight:586.08Org OD 02-0
CAS:<p>10-Ethenyl-19-norprogesterone (Org OD 02-0) is a selective agonist for the membrane progesterone receptor α (mPRα) with an IC50 of 33.9 nM, known to activate</p>Formula:C22H30O2Purity:98%Color and Shape:SolidMolecular weight:326.47FGTI-2734
CAS:<p>FGTI-2734, a dual FT/GGT-1 inhibitor (IC50: 250/520 nM), blocks KRAS membrane binding and curbs KRAS-driven pancreatic cancer.</p>Formula:C26H31FN6O2SPurity:99.69%Color and Shape:SolidMolecular weight:510.63GNE 220
CAS:<p>GNE-220 is a potent and selective inhibitor of MAP4K4 (IC50: 7 nM).</p>Formula:C25H26N8Purity:98%Color and Shape:SolidMolecular weight:438.53HPK1-IN-12
CAS:<p>HPK1-IN-12 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.</p>Formula:C25H24FN5O2Color and Shape:SolidMolecular weight:445.49XRP44X
CAS:<p>XRP44X (XRP 44X) is a potent inhibitor of Ras-Net (Elk-3) pathway.</p>Formula:C21H21ClN4OPurity:99.67%Color and Shape:SolidMolecular weight:380.87KRAS G12D mutation regulator 4
CAS:<p>KRAS G12D mutation regulator 4 can be used in studies about Ras.</p>Formula:C33H33FN6O2Color and Shape:SolidMolecular weight:564.65ERK-IN-2 free base
CAS:<p>ERK-IN-2 free base inhibits ERK2 (IC50: 1.8 nM); potential off-target effects at >10 μM.</p>Formula:C16H17N5O2Color and Shape:SolidMolecular weight:311.34DT-061
CAS:<p>DT-061 is an orally bioavailable protein phosphatase 2A (PP2A) activator. It could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis.</p>Formula:C25H23F3N2O5SPurity:98%Color and Shape:SolidMolecular weight:520.52KRAS G12C inhibitor 16
CAS:<p>KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor.</p>Formula:C24H21ClFN3O3Purity:97.84%Color and Shape:SolidMolecular weight:453.89CXJ-2
CAS:<p>CXJ-2, a cyclic peptide, binds EDPs, inhibits PI3K/ERK, and reduces hepatic cell growth/migration, offering antifibrotic effects.</p>Formula:C55H87N15O22Purity:98%Color and Shape:SolidMolecular weight:1310.37KRAS G12C inhibitor 58
CAS:<p>KRAS G12C inhibitor 58 is utilized in cancer research as an inhibitor of the KRAS G12C mutation [1].</p>Formula:C51H64ClF4N9O8SPurity:98%Color and Shape:SolidMolecular weight:1074.62HPK1-IN-27
CAS:<p>HPK1-IN-27 inhibits HPK1 (MAP4K1), a kinase with potential for cancer treatment, per patent WO2019016071A1, compound 38.</p>Formula:C26H23F3N4O4Color and Shape:SolidMolecular weight:512.48KRAS inhibitor FB9
CAS:<p>KRAS inhibitor FB9 can be used in studies about Ras.</p>Formula:C23H21ClF4N2O5Color and Shape:SolidMolecular weight:516.87KRAS G12D modulator-1
CAS:<p>KRAS G12D modulator-1 (compound 6), a potent modulator of KRAS G12D, exhibits IC50 values ranging from 1-10 μM against NEA-G12D, PPI-G12D, and p ERK-AGS, and is</p>Formula:C30H36FN5O4Purity:98%Color and Shape:SolidMolecular weight:549.64MS934
CAS:<p>MS934, a novel VHL-recruiting MEK 1/2 degrader, exhibits potent anti-proliferative effects on HT-29 cell growth, achieving a GI50 of 0.023 μM.</p>Formula:C52H69F3IN7O6SPurity:98%Color and Shape:SolidMolecular weight:1104.11B-Raf IN 16
CAS:<p>B-Raf IN 16, a BRAF inhibitor, belongs to cyclic iminopyrimidine derivatives and can be used for cancer or tumour research.</p>Formula:C20H19N5O3SPurity:99.31% - 99.78%Color and Shape:SolidMolecular weight:409.46
